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Abstract
Background: Immunotherapy, in particular checkpoint blockade, has changed the clinical landscape of metastatic
melanoma. Nonetheless, the majority of patients will either be primary refractory or progress over follow up.
Management of patients progressing on first-line immunotherapy remains challenging. Expanded treatment
options with combination immunotherapy has demonstrated efficacy in patients previously unresponsive to single
agent or alternative combination therapy.
Case presentation: We describe the case of a patient with diffusely metastatic melanoma, including brain
metastases, who, despite being treated with stereotactic radiosurgery and dual CTLA-4/PD-1 blockade (ipilimumab/
nivolumab), developed systemic disease progression and innumerable brain metastases. This patient achieved a
complete CNS response and partial systemic response with standard whole brain radiation therapy (WBRT)
combined with Talimogene laherparepvec (T-Vec) and pembrolizumab.
Conclusion: Patients who do not respond to one immunotherapy combination may respond during treatment
with an alternate combination, even in the presence of multiple brain metastases. Biomarkers are needed to assist
clinicians in evidence based clinical decision making after progression on first line immunotherapy to determine
whether response can be achieved with second line immunotherapy.
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Background
Immunotherapy (IO) has changed the clinical landscape
for patients diagnosed with metastatic melanoma, with
checkpoint inhibition driving the dramatic improvement
in clinical outcomes over the past 5 years. Ipilimumab, a
monoclonal antibody that blocks cytotoxic T-lymphocyte
associated protein 4 (CTLA-4), an inhibitor of early T-cell
activation and proliferation, was a first in class agent
approved in 2011 [1]. Following ipilimumab, programmed
cell death protein 1 (PD-1) inhibitors, pembrolizumab and
nivolumab, which reduce T-cell suppression at a later
stage in immune response, were developed and demon-
strated higher response rates (25–40% vs. 4–13.9%) when
compared to chemotherapy, in addition to a dramatic
improvement in overall survival (OS) (1-year OS 72.9% vs.
42.1%) [2, 3]. Following the success of these agents,
numerous other immunotherapies have entered develop-
ment and are currently at various stages in clinical trials
with several agents recently approved.
Although these agents have prolonged the lives of many
patients with metastatic melanoma, more than half of
treated patients will not respond, and patients who ini-
tially respond remain at risk for progression [2, 3]. In an
effort to increase the number of patients who may benefit
from IO, as well as enhance the depth of response in
responders, combination immunotherapy approaches
have emerged. Recently, dual CTLA-4/PD-1 inhibition
with ipilimumab/nivolumab has been approved for melan-
oma based on favorable progression free survival (PFS)
relative to nivolumab alone [4].
Talimogene laherparepvec (T-Vec), a first-in-class
therapeutic cancer virus, was approved by the FDA for
the treatment of advanced melanoma in October 2015.
Derived from an attenuated strain of herpes simplex
virus type 1 (HSV-1), the virus has been genetically
modified to secrete granulocyte-macrophage colony-
stimulating factor (GM-CSF) and is administered by dir-
ect injection into accessible melanoma lesions. In
addition to inducing chemotaxis through GM-CSF, the
virus is believed to potentiate a systemic anti-tumor im-
mune response through exposure of tumor antigens fol-
lowing infection of neoplastic cells. T-Vec was approved
based on phase III data showing that patients treated
with T-Vec had a target lesion response rate of 64% and
a systemic overall response rate of 26.4% vs. 5.7% in pa-
tients injected with GM-CSF subcutaneously [5]. For pa-
tients with either multiple soft tissue or visceral
metastasis, reduction, defined as a decrease in tumor
volume of greater than 50%, was seen in 34% of non-
visceral lesions and 15% of visceral lesions [6]. Since its
approval, a trial with combination T-Vec and ipilimu-
mab has suggested synergy with checkpoint inhibition
[7]. There is an ongoing trial of T-Vec with pembrolizu-
mab, with interim analysis demonstrating promising
response rates [8]. Of note, and of particular relevance
to our patient, patients with brain metastasis (BM) were
excluded from all of the above studies.
In melanoma, up to 60% of metastatic melanoma pa-
tients will be diagnosed with brain metastasis over follow
up, and approximately a third of those patients will die
from progression of their brain metastases [9]. Manage-
ment of these patients is challenging in many solid
malignancies, in large part due to most cytotoxic agents
having poor CNS penetrance. Traditional chemotherapeu-
tic agents have been particularly ineffective in manage-
ment of patients with melanoma brain lesions, as these
agents demonstrate poor activity even in the management
of systemic disease. However, several studies indicate that
IO may offer much needed treatment options for patients
with melanoma metastatic to the brain.
Efficacy data for IO in melanoma brain metastasis is lim-
ited as historically these patients have been excluded from
large clinical trials. In a study of IO in the treatment of
brain metastases of various histologies, which included 18
patients with untreated melanoma brain disease, pembroli-
zumab demonstrated similar intracranial and extracranial
disease control rates (42% vs. 50%), with 4 partial responses
and 4 patients with stable disease (SD) on CNS imaging.
After a median follow-up of 11.6 months, median OS had
not been reached [10]. Dedicated melanoma phase II trials
evaluating combination with pembrolizumab and nivolu-
mab are currently underway. While data on combination
therapy is particularly limited, in a small series, 9 patients
with metastatic melanoma, 6 of which had brain metastasis,
were treated with combination IO with nivolumab and low
dose ipilimumab (1 mg/kg), and no increase in neurologic
toxicities were observed [11]. Ipilimumab/nivolumab com-
bination immunotherapy is currently being investigated in
phase II setting (NCT02320058) as well as compared to
monotherapy with nivolumab (NCT02374242), with prom-
ising preliminary data recently released [12–14].
While beyond the scope of this review, targeted ther-
apy, with BRAF and MEK inhibitors, have demonstrated
considerable activity with melanoma brain metastases
[9]. These agent represent critical therapeutic option in
patients with BRAF mutation. Unfortunately, as would
be expected, as seen with systemic disease control, dur-
able responses are rare [9]. As such, patients with mel-
anoma even with brain metastases, are in need in new
therapeutics.
Case presentation
A 68 year-old male with a past medical history of a dis-
tant and previously excised melanoma of unknown
depth on his back, presented in January 2016 with a new
skin lesion on his right forearm. The lesion was 1.5 cm
in diameter, and ulcerated. He was additionally noted to
have a firm right axillary mass. A biopsy of the arm
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lesion was performed and was notable for an 8.7 mm
deep ulcerated melanoma with 5 mitotic figures/mm2.
PD-L1 and BRAFV600E were negative by immunohisto-
chemistry (IHC). Next generation sequencing performed
on tumor tissue demonstrated an NRAS 182A > T Q61L
mutation. Fine needle aspiration (FNA) of the axillary
node was simultaneously performed and confirmed re-
gional melanoma metastasis. A positron emission tom-
ography (PET) scan demonstrated diffuse distant
metastasis, including hypermetabolic lesions in the left
sacrum, ilium, sternum, and several hypermetabolic en-
larged right axillary nodes, the largest of which mea-
sured 5.2 × 3.2 cm. A brain magnetic resonance imaging
(MRI) revealed two small parenchymal lesions in the
right frontal lobe with diameters of 7.7 and 4.3 mm and
a right cerebellar lesion. The patient underwent Gamma-
Knife radiosurgery to all detectable lesions and was
started on combination ipilimumab/nivolumab.
Unfortunately, following two doses of combined ipili-
mumab/nivolumab, CNS imaging revealed numerous
new brain metastases, bilaterally. The lesion in the left
anterior parietal lobe had increased from 7x9x7 mm to
12x15x14 mm (Fig. 1a). In late April, whole brain radi-
ation therapy (WBRT) was recommended, which in-
cluded 3750 cGy in 15 daily fractions. Checkpoint
inhibition was initially continued despite CNS progres-
sion on MRI, as the patient had softening of his nodal
metastases on upper extremity, which was felt to poten-
tially represent systemic response, but was subsequently
discontinued following his fourth cycle as he had pro-
gression of disease on clinical exam with increase in size
of his lymphadenopathy.
At this point, systemic chemotherapy was discussed, but
after the patient refused this option, a trial of pembrolizu-
mab and T-Vec was administered. An initial dose of 4 mL
(106 plaque forming units (PFU)/mL) of T-Vec was
injected into his dominant axillary mass that measured 7.
5 cm in diameter. Two weeks after initiation of T-Vec, the
patient received his first dose of pembrolizumab immedi-
ately following completion of WBRT. The patient contin-
ued receiving T-Vec every 2 weeks and pembrolizumab
every 3 weeks with visible diminishment in size of injected
lesions and the axillary lesion resolving to two separate le-
sions, each measuring approximately 2.5 cm.
Notably, in late July, 11 weeks after initiating T-
Vec, a brain MRI revealed a decrease in size of his
metastatic lesions with associated decrease in sur-
rounding vasogenic edema and no new lesions noted
(Fig. 1b). PET/CT demonstrated a mixed response
with improvement of disease in liver, bones and
injected axilla, while there appeared to be an increase
in other nodal sites. Over follow up, he had repeat
PET scans which continued to demonstrate a mixed
systemic response, however, his brain imaging demon-
strated continued response to therapy (Fig. 1c). In
total, he received 13 treatments of T-Vec over
6 months, prior to discontinuation for disease pro-
gression with development of new bone lesions and
enlarging lymphadenopathy (Fig. 2). The patient did
not experience any grade 3–4 toxicities while receiv-
ing T-Vec and pembrolizumab. His main complaint
was significant fatigue and memory impairment,
which was likely polyfactorial and due to WBRT, CNS
metastasis, as well as related to IO. While on ipilimu-
mab/nivolumab he developed a transient diarrheal ill-
ness which resolved without intervention and a rash
which required topical corticosteroids. He died
16 months after initially being diagnosed with meta-
static melanoma of innumerable brain metastases.
Of interest, our patient consented to enrollment on a
bio-specimen collection protocol at our institution for
the purposes of evaluating biomarkers predictive of re-
sponse to IO in metastatic melanoma. As such, we per-
formed quantitative multiplex immunofluorescence
Fig. 1 CNS response following radiotherapy and immunotherapy. a CNS lesions following gamma knife surgery (GKS), prior to whole brain
radiation therapy (WBRT) and Talimogene laherparepvec (T-Vec). b Three months post WBRT and initiation of T-Vec (c) Six months
following T-Vec
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(qmIF) on his pre-treatment tumor tissue. QmIF allows
for simultaneous (“multiplex”) evaluation of up to 7 anti-
gens on the same full section tissue slide using propri-
etary secondary fluorophores (PerkinElmer) of distinct
wavelengths that can be independently visualized after
image capture using a multispectral camera (Fig. 3). This
pathology evaluation platform has been validated for tis-
sue evaluation in the research setting [15].
QmIF analysis showed that within his primary
tumor, our patient exhibited a high density of CD3
positive cells, approximately 62.4% of nucleated cells
in the stroma, with 3.2% co-expressing CD8. PD-L1
expression on tumor cells was 0% on all evaluated
fields. Macrophages (CD68+) comprised a minute
subpopulation of immune cells and were exclusively
found in the stroma (Fig. 4).
Discussion
Combination immunotherapy
Despite IO offering durable treatment options for many
patients living with metastatic melanoma, nearly half of
treated patients will not respond, even with combined
checkpoint inhibition. T-Vec is distinct from other IO
agents currently available, in part, as it is locally admin-
istered but still demonstrates the capacity to induce re-
sponse in non-injected lesions through systemic
immune activation. This antitumor effect is likely due to
both the cytotoxic capacity of T-Vec, resulting in in-
creased neoantigen exposure to host antigen presenting
cells (APC) following tumor lysis, as well as its ability to
modulate the tumor immune microenvironment (TME).
In the phase II study of T-Vec in melanoma, post-
treatment tumor biopsies were obtained, and treated
Fig. 2 Timeline of the patient’s clinical course. GKS = Gamma knife surgery, WBRT =Whole brain radiotherapy. Ipi/Nivo = Concurrent ipilimumab
and nivolumab
Fig. 3 Representative tissue analysis using Quantitative Multiplex Immunofluorescence (qmIF). a 4 μm tissue section slide is processed using
sequential qmIF protocol which uses tyrosine signal amplification following application of secondary antibody. After tissue processing,
multispectral tissue images are obtained. b Cellular phenotyping is performed using companion software (inForm) which uses machine learning
to perform automated cell phenotyping based on representative cell selection producing a Cartesian map with the X,Y coordinates of each cell
in the imaged tissue, along with its assigned phenotype. c Spatial analysis can be performed using a variety of approaches including nearest
neighbor calculation. As an example, distance between tumor cells (SOX10+) and nearest neighboring CTL (CD3 + CD8+) is being depicted
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patients were observed to have lower levels of immuno-
suppressive cell types including CD4 + FOXP3+ regula-
tory T-cells and myeloid derived suppressor cells
(MDSCs) within the TME of injected lesions as com-
pared to reference controls [5]. In two patients for
whom biopsies of both injected and non-injected tumors
were available, the non-injected lesions demonstrated a
phenotype containing intermediate levels of these im-
munosuppressive subtypes as compared to biopsy data
from untreated patients. These findings suggest that T-
Vec may promote a more effective antitumor immune
response.
However, while non-injected lesions do regress with T-
Vec, the systemic response rates are significantly lower
than those seen with PD-1 checkpoint inhibition. Mod-
est response rates in visceral metastasis seen with T-Vec
suggest that this agent may be most effective when used
in combination with other IO agents, including check-
point inhibitors, which can re-activate exhausted T-cells.
Ipilimumab, as well as pembrolizumab, have both been
evaluated in the phase I setting with T-Vec, with sig-
nificantly higher response rates appreciated, particu-
larly at non-target sites, than with T-Vec alone. When
combined with ipilimumab, 52% of non-target index
lesions demonstrated regression with an immune
related response criteria (irRC) overall response rate
of 50% (4 complete responses, 5 partial responses),
which is dramatically higher than the approximately
10% response rate seen with ipilimumab alone [5].
While patients with brain metastasis were excluded
from these studies, our patient’s response to T-Vec
and pembrolizumab suggests that this combination
can result in a systemic immune response capable of
treating disease within the CNS.
Fig. 4 Cellular phenotyping of the tumor immune microenvironment (TME). a T Cell infiltration – Total CD3 vs. CTL infiltration in tumor (dark)
and stroma (light) (b) Cytotoxic T cell (CTL) activation by tissue location and activation status, HLADR+ active/HLA-DR- inactive. c CD68
distribution by location. d SOX10+ PDL1 expression. Of note, representative tissue images did not include any PDL1+ CD68 cells or PDL1+ tumor
(SOX10+) cells
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Management of melanoma brain metastasis with
immunotherapy
As was the case for our patient, complications associated
with CNS metastases is a leading cause of cancer related
mortality in melanoma. Response data for melanoma
brain metastasis with IO is limited as these patients were
excluded from landmark IO clinical trials.
However, following the promising preliminary re-
sponse data in the phase I setting, multiple dedicated
trials that focus specifically on patients with melanoma
brain metastasis are underway. These studies are de-
signed to evaluate treatment efficacy on CNS related
endpoints including intracranial response (ICR), func-
tional status, and survival without neurologic decline,
and will provide critical insight on the use of IO for
asymptomatic and symptomatic brain metastasis [16].
Currently, a three-arm phase II trial, which includes two
cohorts of patients with asymptomatic brain lesions
treated with either ipilimumab/nivolumab for four doses
followed by nivolumab biweekly (cohort A) or nivolu-
mab monotherapy (cohort B), is underway. The study
also includes a third cohort (cohort C) receiving nivolu-
mab monotherapy with symptomatic or refractory brain
metastasis or leptomeningeal disease, a subpopulation of
patients that have never been included in earlier trials.
The principal endpoint is ICR with secondary endpoints
including extracranial response, overall response rate
(ORR) and PFS/OS. Preliminary results initially reported
at the ASCO 2017 Annual Meeting, and recently
updated at the 2017 World Congress of Melanoma
meeting, are promising with patients treated with ipili-
mumab/nivolumab achieving the highest ICR of 46%,
double the 20% observed in cohort B. Cohort C had the
lowest ICR (6%) [12, 13]. As would be expected, grade
3–4 toxicities were most common in Cohort A (43%),
driven by ipilimumab, and similar to those seen in prior
studies. Of note, neurological adverse events were rare
(6%), occurring in only 4 patients, with one patient de-
veloping radionecrosis [12]. One seizure and two head-
aches were deemed to be related to treatment [12]. A
similar ICR rate of 56%, was seen in patients treated
with ipilimumab/nivolumab on CheckMate 204, also
presented at the ASCO 2017 Annual Meeting [14].
The prognosis of melanoma brain metastases patients re-
quiring WBRT is poor with 3 to 4 months survival. Melan-
oma is considered to a highly radioresistant tumor, and
most of these patients have continued cranial progression.
On our review of the literature we are unable to identify a
published complete ICR to WBRT alone in the setting of
multiple melanoma brain metastases [17–20]. However
there is mounting evidence that the radiation response may
be synergistic when used in combination with IO [21, 22].
Radiation, like oncolytic viral therapy, offers the possibility
of increased tumor antigen presentation and can participate
in IO-instigated in situ vaccination. Therefore, radiation
could serve to augment an effective systemic immune re-
sponse. Frequently referred to as the “abscopal effect,”
tumor regression has been documented at non-irradiated
sites and been attributed to an anti-tumor immune re-
sponse [23]. However, unfortunately, this phenomenon has
not been to-date reliably invoked in clinical management
and, in fact, in some instances immune suppression has
also been documented in the context of radiation therapy.
These variable findings may be, in part, due to the total
dose of radiation delivered or the dosing schedule [24–26].
Several studies are currently underway, which will hopefully
provide additional insight into how radiation can be used to
enhance the activity of IO (NCT02716948, NCT02858869).
Predictive & prognostic biomarkers in melanoma
With new IO agents in development and the rise of com-
bination IO, there is a need for accurate biomarkers to as-
sist clinicians in determining which patients are most
likely to respond to IO, as well as which patients would be
expected to respond to alternative IO therapy at progres-
sion of disease. For ipilimumab, an increase in tumor-
infiltrating lymphocytes (TILs) as well as a high genomic
mutational load have been shown to be predictive of re-
sponse to therapy [27, 28]. Certain specific mutations, in-
cluding the NRAS mutation detected in our patient, also
have been identified as associated with response to IO
[29]. For anti-PD-1 therapy, TIL profiling, specifically with
an increased density of CD8 T-cells, as well as high PD-L1
expression (≥50% by immunohistochemistry), can identify
patients with the greatest probability of achieving a clinical
response. However, a significant percentage (~ 12%) of pa-
tients with low PD-L1 expression (< 10%) will respond to
treatment [30–32]. Overall, none of these biomarkers are
sufficiently precise at determining which patients are likely
to respond and more importantly, which IO agent might
be expected to be most effective. As such, novel genomic
and tissue based evaluation techniques are currently in de-
velopment with the goal of addressing this need [33].
Among these approaches is qmIF, which can provide a
higher resolution evaluation of the tumor immune
microenvironment as compared to traditional IHC. We
include this data as a representative example of the type
of analysis that can be performed. Although this patient’s
tumor showed a significant degree of TIL infiltration,
described by the evaluating pathologist as varying from
focally “non-brisk” to “brisk,” the population of CTL
(CD3 + CD8+), which are known to be critical in anti-
tumor response to programmed death-ligand 1 (PD-L1)
therapy, were consistently low [28]. Furthermore, PD-L1
expression, on tumor cells, albiet of limited utility, was
also absent. While clinically validated biomarkers are re-
quired, we speculate that despite having a low CTL
density, the CD3 population (presumably comprised of
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CD4+ cells, including T regulatory cells) detected with
qmIF, may have been suggestive of the potential fora re-
sponse to immunotherapy. Of note, while our patient
would not have been a candidate for MASTERKEY-26
trial due to symptomatic brain metastases, our findings
are consistent with the corollary studies performed on
tumor specimens obtained on this trial. In this phase Ib
cohort (n = 21), response to combined T-Vec/pembroli-
zumab did not correlate with baseline CTL infiltration
[34]. These findings, would suggest, that oncolytic viral
therapy may be capable of augmenting the activity of
anti-PD-1 therapy even in patients with a “non-favor-
able” TME.
In this case, qmIF was performed on this patient’s pri-
mary lesion prior to receiving any immunotherapy treat-
ment, however this analysis can be performed on the
TME of metastatic tumors, including the CNS, and may
provide additional insight into immunoediting mecha-
nisms unique to the CNS. Clinicopathologic studies indi-
cate that the CNS is not an “immune-privileged” organ
and multiple studies have demonstrated that CNS me-
tastasis frequently resembles primary tumors with
regards to immune infiltrate [35]. TIL infiltration, when
seen in the CNS, similar to extracranial lesions, has
demonstrated prognostic importance when found in the
TME of melanoma brain lesions [36].
However, as new therapies are developed, access to the
TME should not be assumed to be the same between ex-
tracranial and intracranial metastases as there are unique
features of the TME in the CNS which warrant specific
evaluation for their functional and prognostic implica-
tion. These include microglial cells which are known to
be capable of antigen presentation and can express PD-
L1, as well as the absence of high endothelial venules,
which are postulated to enhance immune cell recruit-
ment into the TME [9, 37].
Conclusion
Our patient benefited significantly from combination im-
munotherapy with Pembrolizumab and T-Vec, a first in
class viral IO therapy approved for the treatment of mel-
anoma. Immunomodulating therapies such as radiation
and combination IO can offer non-chemotherapeutic
treatment options for patients who are either refractory
to initial IO treatment or demonstrate progression of
disease. Our patient was primary refractory to ipilimu-
mab/nivolumab, thus treatment options were limited.
Our patient’s clinical response to T-Vec/pembrolizu-
mab following WBRT underscores the benefit that com-
bination IO and synergistic therapies can offer patients,
even following progression on dual checkpoint inhib-
ition. The CNS response observed also underscores the
importance of including patients with melanoma brain
metastasis in future clinical trials with novel IO agents
as they are developed. Clinicopathologic research focus-
ing on the TME of both CNS and non-CNS melanoma
lesions can reveal the critical components of an effective
anti-tumor immune response, as well as mechanisms of
immune escape. Ultimately these features will permit
identification of precise biomarkers and development of
future IO agents for the treatment and management of pa-
tients who are refractory to currently available therapies.
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